Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > Sadly, I Think It's Checkmate
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(370)
•••
Comment by OttawaPeteron Jan 17, 2023 8:57pm
130 Views
Post# 35229576

RE:Sadly, I Think It's Checkmate

RE:Sadly, I Think It's CheckmateJD,appreciate you reading through the materials & providing your perspective, you have worked hard & deserve to be paid-but Sorry, man. I don't take comfort in this at all. DR & BOD didn't do their jobs- they have screwed us out of our investment in BTI -DR & BOD will profit from this deal, no doubt. it is a slap in the face to those of us that carried the company & kept it going all of these years.This deal is absurd & either way there are many of us that will lose a significant amount- if not most of- our investment.So either way we lose.DR & BOD gain from our loss by ignoring their fiduciary responsibilities since 2019? Call me petty-I don't care-- I'm still a NO vote.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities